Reevaluating the GRAVITI Trial of Subcutaneous Guselkumab for Crohn's Disease. Liu J, Shi Y, Yang Y. Gastroenterology 2025 Oct 10:S0016-5085(25)06109.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu J, Shi Y, Yang Y. Reevaluating the GRAVITI Trial of Subcutaneous Guselkumab for Crohn's Disease. Gastroenterology 2025 Oct 10:S0016-5085(25)06109.
PMID: 41077311